EUVIMEDEUVIMED entdecken
Crossref

De novo development strategy for a robust immunocapture-LC-MS/MS assay to quantify soluble fibrinogen-like protein 1 (FGL1) as a potential clinical biomarker for immunotherapy drug development

Naiyu Zheng, Kristin Taylor, Jennifer Postelnek, Sagar Kawle, Huidong Gu, Tracy Tang, Scott Robotham, Nicola Moolman, Ming Lei, Sonia Dolfi, Jianing Zeng, Graham Yearwood und 2 weitere

Analytica Chimica Acta · 2026

DOI: 10.1016/j.aca.2026.346269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytica Chimica Acta, 2026. Verfasst von Naiyu Zheng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine, Bioanalytical & Translational Sciences (PMBATS), Bristol Myers Squibb, Princeton, NJ, 08543, USA. Electronic address: naiyu.zheng…. Hauptthemen laut MEDLINE: Fibrinogen, Immunotherapy, Drug Development. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

De novo development of immunocapture-LC-MS/MS assays to quantify low-abundance protein biomarkers remains challenging due to requirements for high sensitivity, specificity, and robustness. Assay development is often complicated by uncertainties associated with post-translational modifications (PTMs), surrogate peptide selection, antibody performance, and unknown endogenous concentration ranges. To address these challenges, we developed a systematic, four-stage de novo development strategy consisting of: (1) in silico digestion to identify surrogate peptide candidates; (2) optimization of LC-MS/MS conditions and enzymatic digestion conditions; (3) confirmation of antibody performance against endogenous proteins; and (4) evaluation of endogenous protein concentrations. With this strategy, we developed, to our knowledge, the first immunocapture-LC-MS/MS assay to quantify total soluble fibrinogen-like protein 1 (FGL1) in human serum, a major ligand of lymphocyte activation gene-3 (LAG-3) involved in T-cell suppression. The assay utilized IRPNDFIPNVI as the surrogate peptide and mouse serum as the surrogate matrix. After immunocapture enrichment with an anti-FGL1 antibody, the surrogate peptide and internal standard (IS) were separated by reversed-phase UHPLC and detected on a SCIEX Triple Quad 6500+ system using MRM transitions of m/z 649.4 → 856.5 for IRPNDFIPNVI peptide and m/z 652.4 → 856.5 for IRPNDFIPN{VAL(13C5,15N)}I as the internal standard. The assay achieved a calibration range of 10-1000 ng/mL with sufficient sensitivity to enable quantification of FGL1 in serum samples collected from cancer patients. Fit-for-purpose validation using analytical and endogenous quality control samples showed intra-assay precision ≤7.4% CV and inter-assay precision ≤5.2% CV. This assay has been successfully applied in clinical studies to support evaluation of FGL1 as a potential clinical biomarker for immunotherapy drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrinogenImmunotherapyDrug DevelopmentHumansTandem Mass SpectrometryAnimalsMiceLiquid Chromatography-Mass SpectrometryBiomarkersChromatography, LiquidLymphocyte Activation Gene 3 Protein

Stichwörter der Autor:innen

Anti-LAG-3 immunotherapyDe novo assay developmentEndogenous protein biomarker quantitationFibrinogen-like protein 1 (FGL1)Fit-for-purpose validationImmunocapture-LC-MS/MS

Substanzen

FibrinogenFGL1 protein, humanBiomarkersLymphocyte Activation Gene 3 Protein

Autor:innen und Institutionen

  • Precision Medicine, Bioanalytical & Translational Sciences (PMBATS), Bristol Myers Squibb, Princeton, NJ, 08543, USA. Electronic address: naiyu.zheng@bms.com.
  • Precision Medicine, Bioanalytical & Translational Sciences (PMBATS), Bristol Myers Squibb, Princeton, NJ, 08543, USA.
  • Translational Bioinformatics, Bristol Myers Squibb, Princeton, NJ, 08543, USA.
  • Translational Development, Bristol Myers Squibb, Princeton, NJ, 08543, USA.

Zitieren

APA

Zheng, N., Taylor, K., Postelnek, J., Kawle, S., Gu, H., Tang, T., Robotham, S., Moolman, N., Lei, M., Dolfi, S., Zeng, J., Yearwood, G., Xue, Y., & Shen, J. X. (2026). De novo development strategy for a robust immunocapture-LC-MS/MS assay to quantify soluble fibrinogen-like protein 1 (FGL1) as a potential clinical biomarker for immunotherapy drug development. Analytica Chimica Acta. https://doi.org/10.1016/j.aca.2026.346269

Vancouver

Zheng N, Taylor K, Postelnek J, Kawle S, Gu H, Tang T, et al. De novo development strategy for a robust immunocapture-LC-MS/MS assay to quantify soluble fibrinogen-like protein 1 (FGL1) as a potential clinical biomarker for immunotherapy drug development. Analytica Chimica Acta. 2026. doi:10.1016/j.aca.2026.346269

BibTeX
@article{Zheng2026,
  author = {Zheng, Naiyu and Taylor, Kristin and Postelnek, Jennifer and Kawle, Sagar and Gu, Huidong and Tang, Tracy and Robotham, Scott and Moolman, Nicola and Lei, Ming and Dolfi, Sonia and Zeng, Jianing and Yearwood, Graham and Xue, Yongjun and Shen, Jim X},
  title = {De novo development strategy for a robust immunocapture-LC-MS/MS assay to quantify soluble fibrinogen-like protein 1 (FGL1) as a potential clinical biomarker for immunotherapy drug development},
  journal = {Analytica Chimica Acta},
  year = {2026},
  doi = {10.1016/j.aca.2026.346269}
}
Kostenlos starten →